The modern look on the platinum-based chemotherapy effectiveness the modern look on the platinum-based chemotherapy effectiveness
DOI:
https://doi.org/10.12775/JEHS.2025.81.66051Keywords
ovarian cancer, treatment, chemotherapy, platinoresistance, platinorefraction, quality of lifeAbstract
The aim of the work is to assess the quality of life in platinum-resistant patients with ovarian cancer, depending on the degree of pharmacoresistance and differentiated use of chemotherapy.
Materials and methods. The study was conducted on the basis of the University Clinic of the Odessa National Medical University during 2014 - 2020 years. 350 patients with adenocarcinoma of the ovaries of III-IV stage were examined, who performed cytoreductive operations.
Results and discussion. It is shown that the initial values on the subscales of the questionnaires EORTC QLQ-C30 and FACT-G in patients classified as different clinical groups were compared. When using a differentiated approach in the treatment of patients with OC, the indicators on the scales of physical (PF), role (RF) and emotional functioning (EF) were significantly improved. In addition, the intensity of nausea (NV) and general weakness (FA) decreased in patients of groups III and IV. In the case of differentiated use of chemotherapeutic agents with metabolic support, the total score according to the FACT-G questionnaire was 77.8±0.9 points in group III, and 77.9±0.8 points in group IV, which significantly exceeds the received in I and II groups - 72.2±1,2 and 71,6±0,9 points. The described differences were kept throughout the period of catamnestic observation.
Conclusions: The use of a differentiated approach in the treatment of patients with RI significantly improved indicators on the scales of physical (PF), role (RF) and emotional functioning (EF). After treatment, the intensity of nausea (NV) and general weakness (FA) decreased in patients of groups III and IV. The described differences were retained for 12 months after the completion of the course of treatment. Prospects for further research are related to the study of the dynamics of life quality of patients with OC at the subsequent stages of catamnestic observation.
References
1. Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, Kelemen LE, Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J Natl Cancer Inst. 2023 Oct 1; 109(10).
2. Bondar, O.V., Rybin, A.I., Muzyka, V.V. Experience of primary HPV testing in cervical cancer screening. Odesa Medical Journal, 2022, 2022(1-2), pp. 93–96. DOI 10.54229/2226-2008-2022-1-2-16.
3. Bondar O, Rybin A, Patskov A. The quality of life of ovarian cancer patients as an indication of effectiveness of platinum-based adjuvant chemotherapy. Georgian medical news 2021; (11): 32–6. https://repo.odmu.edu.ua:443/xmlui/handle/123456789/10608.
4. Bondar O, Rybin A. The experience and results of cytoreductive surgery and HIPEC used in advanced ovarian cancer. ScienceRise 2020; (5): 19–23. https://doi.org/10.21303/2313-8416.2020.001458.
5. Bondar O, Rybin A., Kuznetsova O. Prophylactics of paclitaxel-induced neurotoxicity. Collection of Scientific Papers «ΛΌГOΣ», (July 21, 2023; Paris, France), 180–186. https://doi.org/10.36074/logos-21.07.2023.53
6. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2022; 68(6):394-424. https://doi.org/10.3322/caac.21492.
7. Chandra A, Pius P, Nabeel M, et al. Ovariancancer: Current status and strategies for improving therapeutic outcomes. Cancer Med 2019; 8 (16): 7018–31. doi: 10.1002/cam4.2560.
8. Cortez AJ, Tudre P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018; 81 (1): 17–38. doi: 10.1007/s00280-017-3501-8.
9. Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 2009; 100 (4): 321–8. https://doi.org/10.1002/jso.21388.
10. Deraco M, Virzì S, Iusco D, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG 2012; 119 (7): 800–9. https://doi.org/10.1111/j.1471-0528.2011.03207.
11. Di Vita M, Cappellani A, Piccolo G, et al. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anticancer Drugs 2015; 26 (2):123–38. https://doi.org/10.1097/cad.0000000000000179.
12. Kolesnik O.O., Rybin A.I. Predicting the effectiveness of treatment for ovarian cancer patients. Current issues in paediatrics, obstetrics and gynaecology. – 2017. – No. 2. – pp. 40–47. DOI 10.11603/24116-4944.2017.2.8043.
13. Kolesnik O.O., Rybin A.I. Personalised treatment of ovarian cancer patients. Hospital Surgery. Journal named after L. Ya. Kovalchuk. – 2017. - No. 2 (78). – Pp. 5-12. DOI 10.11603/2414-4533.2017.2.7951.
14. Rybin A. (2022). Results of personalised treatment of ovarian cancer in patients with peritoneal carcinomatosis // Reproductive Health of Women, (7), 35–40. https://doi.org/10.30841/2708-8731.7.2022.272470.
15. RYBIN, A., MAKSYMOVSKYI, V., KUZNETSOVA, O. and ZAMYSHLYAK, V. Personalised treatment of patients with advanced ovarian cancer: comparative analysis of surgical approaches. Journal of Education, Health and Sport. Online. 30 June 2025. Vol. 83, p. 64576. DOI 10.12775/JEHS.2025.83.64576.
16. MAKSYMOVSKYI, V., RYBIN, A. and ZAMYSHLYAK, V. Quality of life in patients with advanced ovarian cancer under personalised treatment: the impact of HIPEC. Journal of Education, Health and Sport. Online. 11 August 2025. Vol. 84, p. 64751. DOI 10.12775/JEHS.2025.84.64751.
17. Rybin AI, Maksymovskyj VY, Pyrogov VV, Demidchik RY, Varabina AO. Comparative study of quality of life, adverse effects after cytoreduction and HIPEC in stage IIIA-IIIC ovarian cancer. J Educ Health Sport [Internet]. 2018 Oct. 31 8(10):412-7. DOI http://dx.doi.org/10.5281/zenodo.2456541
18. Rybin A.I. The role of proteomic and genetic predictors of survival in ovarian cancer patients. Clinical Oncology, 2016, No. 3 (23), pp. 46-48.
19. Prevention of pathological changes in the mammary glands in patients after surgery for uterine fibroids / S.G. Bugaysov, A.I. Rybin, A.E. Suprun // Oncology. — 2007. — Vol. 9, No. 2. — Pp. 129–132. https://nasplib.isofts.kiev.ua/handle/123456789/20479.
20. Rybin AI, Kuznetsova OV. Second line of the ovarian cancer treatment: from clinical researches to realties of war. Grail of Science, (26), 478–482. https://doi.org/10.36074/grail-of-science.14.04.2023.085
21. Rybin AI, Kuznetsova OV, Maximovsky VE. Modern strategies of surgical treatment of patients with pelvic canceromatosis caused by the ovarian cancer. Visnyk morsʹkoyi medytsyny 2020; 2 (87): 55–61. http://dx.doi.org/10.5281/zenodo.3967728.
22. Rybin AI, Kuznetsova OV, Patskov A.O. Optimizing of management of the ovarian cancer patients with peritoneal carcinomatosis. Sworld Journal. – 2024. – Issue 23, Part 2. – P.15-24. DOI: 10.30888/2663-5712.2024-23-00-014.
23. Rybin A.I., Varabina A., Borshkov M. Epidemiology and management of ovarian cancer based on the clinical experience of the southern region of Ukraine. Georgian medical news 2019; 3 (288): 32–37. https://repo.odmu.edu.ua:443/xmlui/handle/123456789/7511.
24. Rybin AI, Demidchik RYa. Quality of life of patients with ovarian cancer after cytoreductive surgery and chemotherapy. Аctual problems transport medicine 2018; 4 (54): 59–63. http://dx.doi.org/10.5281/zenodo.252578612.
25. Rybin A.; Dubinina V.; Kuznetsova O. The Prognosis Of Resistance To Platinum Drugs In Patients With The Serous Ovarian Cancer. Intenational Journal of Gynecological cancer. 2016 -Volume 26. - P. 36-37. WOS:000387108300020.
26. Tkachenko ОІ, Rybin AI, Kuznetsova OV, Maximovsky VE. Modern strategies of surgical treatment of patients with ovarian cancer combined with pelvic carcinomatosis. Clin oncol 2018; 8 (3): 1–7. https://repo.odmu.edu.ua:443/xmlui/handle/123456789/7250.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 A. Rybin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 68
Number of citations: 0
